Evotec Biologics and BARDA to Optimize Filovirus Antibody Manufacturing
In a significant development for public health preparedness, Evotec Biologics, a subsidiary of Evotec SE, has entered into a project agreement with the Biomedical Advanced Research and Development Authority (BARDA) to optimize the manufacturing of monoclonal antibodies targeting Ebola and Sudan viruses. This initiative is a critical step toward enhancing the United States’ preparedness for hemorrhagic fever outbreaks.
Project Overview
The multi-year program, managed under the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), is valued at up to $10 million. It aims to support the development of cost-effective medical countermeasures by optimizing the production of a monoclonal antibody cocktail that targets both Ebola virus (EBOV) and Sudan virus (SUDV) infections. While treatments for Ebola virus disease are available, no FDA-approved therapies exist for the Sudan virus, highlighting the urgency of this project.
Technological Advancements
Just – Evotec Biologics will employ its advanced biomanufacturing platform, leveraging AI/ML technologies and molecular design, to enhance the scalability and robustness of production processes. This approach is designed to ensure that these life-saving treatments can be produced at high yields and rapidly deployed during public health emergencies.
Linda Zuckerman, PhD, EVP Global Head of Biotherapeutics at Just – Evotec Biologics, emphasized the importance of speed and scalability in outbreak scenarios. The company’s technology-driven strategy aims to deliver resilient, industry-leading production processes that can support rapid deployment.
Biopharmaceutical Manufacturing Preparedness Consortium
The BioMaP-Consortium, comprising industry partners across the drug and vaccine manufacturing supply chain, supports BARDA’s mission to secure medical supplies and prepare for future health security threats. The consortium focuses on expanding the industrial and manufacturing base for medical countermeasures, ensuring flexibility and capability in response to emergencies.
About BARDA
BARDA, part of the U.S. Department of Health and Human Services, is responsible for the advanced research, development, and procurement of medical countermeasures against chemical, biological, radiological, and nuclear threats, as well as pandemic influenza and emerging infectious diseases.
About Just – Evotec Biologics
Just – Evotec Biologics is a pioneering biologics platform company that utilizes AI/ML technologies and advanced manufacturing strategies to accelerate the development of biotherapeutics. With a strong focus on scientific and technological innovation, the company aims to improve accessibility and affordability of treatments.
About Evotec SE
Evotec SE is a life science company dedicated to revolutionizing drug discovery, and development. By integrating breakthrough science with AI-driven innovation, Evotec accelerates the journey from concept to cure, offering flexible partnering models across various therapeutic areas.
Conclusion
This partnership between Evotec Biologics and BARDA represents a pivotal advancement in the fight against life-threatening filoviruses. By optimizing the manufacturing of critical medical countermeasures, the project strengthens the U.S. Government’s response capabilities, ensuring better preparedness for future outbreaks.
This article synthesizes the verified information from the provided sources, ensuring accuracy and relevance while maintaining an engaging and authoritative tone.